SecBot SecBot
SECBOTREPLAY Home › Report › WVE

WVE · Wave Life Sciences released positive Phase 1 data for WVE-007, an…

Wave Life Sciences USA, Inc. · PRESS-RELEASE filed Mar 26, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 26, 2026 at 07:30 ET

Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant and durable reductions in visceral fat (-14% vs. placebo) and improved body composition six months after a single dose. The results support advancement into Phase 2a trials in higher-BMI patients in 2Q 2026 and suggest potential in MASH, type 2 diabetes, and cardiovascular disease. The therapy continues to show a favorable safety profile.

  • Single 240 mg dose of WVE-007 led to -14.3% placebo-adjusted reduction in visceral fat at 6 months (p<0.05)
  • Total fat reduced by -5.3%, waist circumference by -3.3%, body weight by -0.9%, with lean mass preserved (+2.4%)
  • Visceral fat-to-muscle ratio (VMR) improved by -16.5%, outperforming semaglutide's -12.2% in a higher-BMI population
  • Serum Activin E suppressed up to 88%, supporting potential for once- or twice-yearly dosing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access